Book a demo

Chemical intelligence powered by cypris.ai

Iophendylate

ethyl 10-(4-iodophenyl)undecanoate · also: Myodil, Myodyl, Ethiodan, Mulsopaque, Pantopaque, Neurotrast

FormulaC19H29IO2
Mol. weight416.3435
PubChem CID7458
InChIKeyLAYLQVBQIBQVLL-UHFFFAOYSA-N
SMILESCCOC(=O)CCCCCCCCC(C)C1=CC=C(C=C1)I
587Patents
277Research papers
25Patents - last 3 years
1Papers - last 3 years

Who owns the IP

The organizations most actively patenting around this compound, ranked by referenced patent volume.

#AssigneePatents
1Boston Scientific Scimed Inc24
2GE Healthcare AS24
3Entero Therapeutics Inc17
4GridAI Technologies Corp17
5Boston Scientific Corp15
6Hyperbranch Medical Technology Inc15
7Aquestive Therapeutics Inc13
8Cornell University13
9Institut National de la Santé et de la Recherche Médicale12
10Boston Scientific Ltd Barbados10

Explore the full landscape

This preview shows the leading assignees. Cypris reveals the full ownership landscape - every filing entity, filing trends, and portfolio momentum.

Visit Cypris

Where innovation is concentrated

Patent classifications ranked by volume reveal the technical domains with the most active filing.

#CodeAreaPatents
1A61KMedicinal preparations384
2A61PTherapeutic activity (drug indications)234
3A61LSterilising / disinfecting materials130
4C08LPolymer compositions (blends)106
5A61B53
6A61F46
7C07CAcyclic and carbocyclic compounds39
8C07KPeptides36
9C07DHeterocyclic compounds31
10C08FPolymers from C=C unsaturated bonds30

AI mapped opportunity space

This preview shows where patent activity concentrates. Cypris maps the full classification landscape to surface technical whitespace and IP headroom.

See Cypris in action

Where research is gaining momentum

Research themes ranked by publication activity show where scientific interest is accelerating around this compound.

#Research topicPapers
1Traumatic Brain Injury and Neurovascular Disturbances2
2Advanced X-ray and CT Imaging1
3Barrier Structure and Function Studies1
4Pediatric Urology and Nephrology Studies1
5Venous Thromboembolism Diagnosis and Management1

Who's driving the science

The most-published authors working with this compound, alongside their primary affiliations.

#AuthorAffiliationPapers
1Amosov Is3
2Robert L. Scanlan3
3A. Basil Harris2
4Alex ChanUniversity of Tennessee at Knoxville2
5Arthur E. RosenbaumPittsburg State University2
6B. E. KendallUniversity College London2
7CW Kerber2
8Erich G. KruegerEastern Research Group (United States)2
9Ganichkin Am2
10Glenn E. JonesUniversity of Rochester2

Research leaders

This preview lists the top authors. Cypris surfaces the full researcher landscape, their affiliations, and how scientific influence is shifting.

See Cypris in action

The literature that defines it

The most-cited papers anchoring the scientific record for this compound.

TitleYearCited byTopic
Neurotoxicity of radiological contrast agents1983242Traumatic Brain Injury and Neurovascular Disturbances
Fish under exercise2011181Aquaculture Nutrition and Growth
Extradural block. Confirmation of the injection site by X‐ray monitoring1985163Anesthesia and Pain Management
Modification of cyanoacrylate for therapeutic embolization: preliminary experience1979119Trauma Management and Diagnosis
Long-Term Outcome of Embolotherapy and Surgery for High-Flow Extremity Arteriovenous Malformations2000116Vascular Malformations and Hemangiomas

Frequently asked questions

Common questions about this compound's patent and research landscape, answered from the underlying data.

What is the molecular composition and structure of Iophendylate?

Iophendylate has the canonical name ethyl 10-(4-iodophenyl)undecanoate with molecular formula C19H29IO2 and molecular weight 416.3435. It is also known by several brand names including Myodil, Pantopaque, and Neurotrast, among others.

Which organizations hold the most patents related to Iophendylate?

Boston Scientific Scimed Inc and GE Healthcare AS each hold 24 patents related to Iophendylate, making them the leading patent holders. Entero Therapeutics Inc and GridAI Technologies Corp follow with 17 patents each.

What research topics are most associated with Iophendylate publications?

Traumatic Brain Injury and Neurovascular Disturbances is the most represented topic in the research literature on Iophendylate, appearing in 2 papers. Other topics include Advanced X-ray and CT Imaging, Barrier Structure and Function Studies, Pediatric Urology and Nephrology Studies, and Venous Thromboembolism Diagnosis and Management.

What are the main patent classifications for Iophendylate-related inventions?

The dominant patent classification is A61K (pharmaceuticals and medicinal preparations) with 384 patents, followed by A61P (specific therapeutic activities) with 234 patents. Other significant classifications include A61L (materials for bandages and dressings), C08L (compositions of macromolecular compounds), and A61B (medical instruments and apparatus).

How has patent activity for Iophendylate changed in recent years?

Patent activity shows fluctuation in recent years, with 23 patents filed in 2020 and 18 in 2021, declining to 9 in 2022, then rising to 18 in 2023. Recent years show lower filing rates, with 7 patents in 2024 and 9 in 2025. In contrast, 587 patents total have been issued across the full historical record.

Turn any compound into a complete chemical intelligence landscape

Go beyond static compound data. Cypris resolves identities, patents, papers, and commercial signals into one AI-powered view - so your team can move from a single chemical question to a complete R&D, IP, and market landscape.

Schedule a free trial